JCB, Volume 22, Number 4, 2016 Article Vol.22 No. 4 (2016) Do Venture Capital Firms Play as Supportive Mentors or Free-riders? Evidence from China Xi Yang This paper aims to investigate whether Venture Capital Firms in China play as active investors, who seize to provide the funded entrepreneurial firms monitoring assistance and value-addin Article Vol.22 No. 4 (2016) Leaving money on the table in venture-backed biotechnology IPOs Hans Lennart Jeppsson This study analyzes first-day returns (underpricing) for venture-backed biotechnology IPOs during 1980 through 2015. The result of this study shows that the average first-day return was 1 Article Vol.22 No. 4 (2016) Biotech venture capital investments in public equities and performance Hans Lennart Jeppsson This study examines a large sample of venture investments in public equities (VIPEs) in the biotechnology and pharmaceutical industry over the period 1995-2014. The results of the study a Intellectual Property Management Vol.22 No. 4 (2016) Induced Pluripotent Stem Cells: Inventors turning into competitors Pratap Devarapalli Induced Pluripotent Stem Cells (IPSCs) are a kind of adult cells that have been genetically reprogrammed to become different cell types. Differentiated cells can be reprogrammed to an emb From the Boardroom Vol.22 No. 4 (2016) Emerging Business Models and Strategies to Accelerate Innovation in the Biopharmaceutical Industry Arthur Boni We focus on assessing and addressing the current challenges faced by the companies that comprise the biopharmaceutical industry. These include: improving productivity in the drug deve
